Physician profile
Jack Chelebian
NPI 1295763399
$8,775.09
in general payments reported to CMS, 2019-2025
14 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,008 · 2020: $102 · 2021: $57.89 · 2022: $439 · 2023: $184 · 2024: $776 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.45 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $6,287.50 | 2019 | |
| Alkermes, INC. | $487.32 | 2019-2024 | Lybalvi, Aristada, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $412.03 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $341.42 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $310.58 | 2022-2024 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $296.24 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $182.58 | 2019-2024 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $103.22 | 2019-2024 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $103.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.47 | 2022 | |
| Tris Pharma INC | $76.47 | 2019 | |
| Neurocrine Biosciences, INC. | $55.64 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.47 | 2022 | |
| Indivior INC. | $16.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Chelebian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.